N/A N=55 Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Proportion of Enrolled Participants for Which we Are Able to Collect Data From the Medication Event Monitoring Systems (MEMS^TM) System for Two or More Cycles of…
Phase 2 N=23 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Neurofibromatosis Type 1 · Precancerous Condition
Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months
Phase 2 N=45 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Phase 2 N=5 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
Phase 2 N=9 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
Phase 2 N=14 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Phase 2 N=21 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Phase 2 N=11 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Phase 2 N=62 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
Phase 3 N=66 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Neurofibromatosis Type 1 · Plexiform Neurofibromas
Primary: Mean Pain Interference Mean Score Change From Baseline to 8 Weeks Between the Acceptance and Commitment Therapy Intervention Group and the Waitlist Group — 61.93; 62.87…
N/A N=20 HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy
Cutaneous Neurofibroma
Primary: Short Term Safety Profile - Adverse Events — 0; 20 Participants
Phase 2 N=21 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Neurofibromatosis 2 · Vestibular Schwannoma
Primary: Estimated Volumetric Progression Free Survival at 12 Months — 70.6 Liklihood of PFS at 12 months
Phase 2 N=10 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months